Sarah Cannon Research Institute (SCRI) has acquired Clinical Development Group (CDG), a clinical trial consulting firm based in New Haven, CT. The acquisition expands SCRI’s capabilities in global clinical and regulatory planning, trial project management, and provides access to therapeutic expertise, key opinion leadership and academic relationships.
Additionally, SCRI has opened an office in Cambridge, MA and several experienced members of CDG will join the SCRI Development Innovations business unit. Ann Cahill, president of CDG, will serve as vice president of Program Development and joins SCRI’s executive team. She reports to chief medical officer, Howard A. Burris III, MD. Prior to founding CDG, Ms. Cahill held several leadership positions in drug development with Schering-Plough and Vion Pharmaceuticals.
“The addition of CDG is an important step for SCRI, as we continue to experience rapid growth in the management and oversight of clinical trials,” said SCRI chief executive officer, Dee Anna Smith. “CDG’s strong passion and dedication to oncology research aligns with our values, and we are excited to add these talented members to our team.”